Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Cash Flows (Unaudited)

v3.22.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Cash Flows from Operating Activities    
  Net loss $ (3,891,783) $ (1,407,674)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 3,177 11,571
Share based compensation expense 226,079
Inducement expense 3,024,872
Changes in operating assets and liabilities:    
Accounts receivable 6,262 (40,500)
Patient financing receivable, current portion (11,300)
Other receivables (3,831) 20,986
Prepaid expenses and other assets (148,334) (115,026)
Patient financing receivable, net of current portion (2,456)
Accounts payable 94,913 142,629
Accrued liabilities (14,427) (39,638)
Other current liabilities 111,324 169,789
Deferred revenue (353,098) (52,890)
Interest payable, related parties 39,937
Interest payable 34,406 3,940
Net Cash Used in Operating Activities (884,259) (1,306,813)
Cash Flows from Investing Activities    
Purchase of property and equipment (1,522)
Net Cash Used in Investing Activities (1,522)
Cash Flows from Financing Activities    
Proceeds from warrant exercise related to inducement 1,170,110
Payment on PPP Loan (39,739)
Net Cash Provided by Financing Activities 1,130,371
Net Change in Cash 246,112 (1,308,335)
Cash – Beginning of period 95,172 1,640,645
Cash – End of period 341,284 332,310
Supplementary Cash Flow Information    
Cash paid for interest 1,378 1,844
Non-cash financing activities    
Conversion of Series A Preferred Stock to Common Stock 3,658 9,680
Issuance of warrants pursuant to inducement agreements 2,993,872
Issuance of warrants for services rendered $ 31,000